Ultragenyx Pharmaceutical

(NASDAQ) RARE

Current Price$23.34

Market Cap$2.21B

Since IPO (2014)-47%

5 Year-78%

1 Year-37%

1 Month-7%

Ultragenyx Pharmaceutical Financials at a Glance

Market Cap

$2.21B

Revenue (TTM)

$669.43M

Net Income (TTM)

$609.36M

EPS (TTM)

$-6.11

P/E Ratio

-3.68

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$23.34

Volume

1,547,754.53

Open

$22.55

Price

$23.34

Volume

1,547,754.53

Open

$22.55

Previous Close

$23.37

Daily Range

$22.55 - $23.72

52-Week Range

$18.29 - $42.37

Dividend

$0.00

Beta (Volatility)

1.11 (Average)

Price

$23.34

Volume

1,547,754.53

Open

$22.55

Previous Close

$23.37

Daily Range

$22.55 - $23.72

52-Week Range

$18.29 - $42.37

RARE News

Page 1

RARE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ultragenyx Pharmaceutical

Industry

Biotechnology

Sector

Health Care

Employees

1,371

CEO

Emil D. Kakkis, MD, PhD

Website

www.ultragenyx.com

Headquarters

Novato, CA 94949, US

RARE Financials

Key Financial Metrics (TTM)

Gross Margin

84%

Operating Margin

-84%

Net Income Margin

-91%

Return on Equity

-657%

Return on Capital

-58%

Return on Assets

-47%

Earnings Yield

-27.17%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.21B

Shares Outstanding

98.49M

Volume

1.55M

Avg. Volume

1.90M

Financials (TTM)

Gross Profit

$564.00M

Operating Income

$535.00M

EBITDA

$500.00M

Operating Cash Flow

$466.00M

Capital Expenditure

$6.00M

Free Cash Flow

$472.00M

Cash & ST Invst.

$693.00M

Total Debt

$1.28B

Ultragenyx Pharmaceutical Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$136.00M

-2.4%

Gross Profit

$106.00M

-4.2%

Gross Margin

77.94%

N/A

Market Cap

$2.21B

N/A

Market Cap/Employee

$1.71M

N/A

Employees

1,294

N/A

Net Income

$185.00M

-22.5%

EBITDA

$161.00M

-27.3%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Net Cash

$787.00M

-272.5%

Accounts Receivable

$121.00M

+22.4%

Inventory

$55.00M

+19.5%

Long Term Debt

$1.13B

+3959.6%

Short Term Debt

$72.00M

+586.6%

Return on Assets

-47.02%

N/A

Return on Invested Capital

-57.86%

N/A

Free Cash Flow

$198.00M

-8.3%

Operating Cash Flow

$197.00M

-18.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AAPGAscentage Pharma Group International

AAPGAscentage Pharma Group International$19.78+4.16%

IDYAIDEAYA Biosciences, Inc.

IDYAIDEAYA Biosciences, Inc.$29.65+4.70%

SLNOSoleno Therapeutics, Inc.

SLNOSoleno Therapeutics, Inc.$53.01+0.00%

DYNDyne Therapeutics, Inc.

DYNDyne Therapeutics, Inc.$17.56+10.30%

TVTXTravere Therapeutics, Inc.

TVTXTravere Therapeutics, Inc.$43.49+2.91%

XENEXenon Pharmaceuticals Inc.

XENEXenon Pharmaceuticals Inc.$54.68+1.17%

APGEApogee Therapeutics, Inc.

APGEApogee Therapeutics, Inc.$81.39+3.99%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

AALAmerican Airlines Group

AALAmerican Airlines Group$12.95+0.07%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$14.67+0.06%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$76.51+0.05%

NUNu Holdings

NUNu Holdings$12.79+0.04%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$42.19-0.05%

MARAMara Holdings

MARAMara Holdings$13.15+0.06%

BACBank of America

BACBank of America$51.23+0.01%

Questions About RARE

What is the current price of Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical is trading at $23.37 per share.

What is the 52-week range for Ultragenyx Pharmaceutical?

Over the past 52 weeks, Ultragenyx Pharmaceutical has traded between $18.29 and $42.37.

How much debt does Ultragenyx Pharmaceutical have?

As of the most recent reporting period, Ultragenyx Pharmaceutical reported total debt of $1.20B.

How much cash does Ultragenyx Pharmaceutical have on hand?

Ultragenyx Pharmaceutical reported $183.00M in cash and cash equivalents in its most recent financial results.

What is Ultragenyx Pharmaceutical’s dividend yield?

Ultragenyx Pharmaceutical does not currently have a dividend yield.

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Financials at a Glance

RARE News

Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today

Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today

Ultragenyx (RARE) Q2 Revenue Up 13%

Why Ultragenyx Pharmaceutical Stock Is Cratering Today

Why Ultragenyx Pharmaceutical Stock Surged 23.4% Today

Why Stryker, Ultragenyx Pharmaceutical, and La-Z-Boy Slumped Today

Why Ultragenyx Pharmaceutical Stock Is Sinking Today

Why Ultragenyx Pharmaceutical Stock Is Spiking Today

RARE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ultragenyx Pharmaceutical

RARE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ultragenyx Pharmaceutical Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RARE

What is the current price of Ultragenyx Pharmaceutical?

What is the 52-week range for Ultragenyx Pharmaceutical?

How much debt does Ultragenyx Pharmaceutical have?

How much cash does Ultragenyx Pharmaceutical have on hand?

What is Ultragenyx Pharmaceutical’s dividend yield?

Premium Investing Services